27.97 USD
▼-0.60-2.10%
盘后 29.41 0.00%
2026-09-15
市值
$1.36B
市盈率
—
EPS
-3.70
股息率
—
52 周区间
17.00 – 35.83
成交量
337.27K
Beta
1.36
目标价
44.70
52W 低 17.0052W 高 35.83
价格走势
公司简介
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC...